Patients with CML (chronic myelogenous leukemia) who have received constant treatment with Imatinib (Gleevec) have acquired point mutations in the tyrosine kinase domain of the BCR-ABL fusion gene. Especially, the T315I mutation is known to be a mutation associated with imatinib resistance and is observed with high frequency. It is important to monitor patients treated with the Imatinibby BCR-ABLfusion gene mutation test to prevent failure of therapy due to mutational drug resistance.
PNAClamp™ Mutation Detection Kit BCR-ABL
For the detection of the BCR-ABL-associated T315I mutation
Cat. No. PNAC-7001
Other products
EDTA, disodium salt, dihydrate
Part number: EB0185
BUFFER PBS (PHOSPHATE BUFFERED SALINE) 100 ML TABLETS
50 tablets for 100 mL each one.
PathoSEEK AHP starter kit (200 samples)
The AHP starter kit includes all the reagents a testing...